Invited Speakers

 

Prof. Gerd Multhaup is Professor and Chair of the Department of Pharmacology and Therapeutics at McGill University. He holds a Canada Research Chair (Tier 1) in Molecular Pharmacology. His research interests include understanding the APP biology and investigating the molecular events of amyloid aggregation, gain of toxicity, and the causes of neuronal dysfunction. The primary aim is to identify novel targets to develop pharmacological strategies for prevention and therapy.

 

Dr. Laura Aitken is a post-doctoral research fellow at the University of St. Andrews. Dr Aitken earned her BSc. (Hons) in Pharmaceutical Chemistry from the University of Dundee, 2008 and received her Ph.D in Neurobiology from the University of St. Andrews in 2013. After a brief spell in Industry she returned to St. Andrews to investigate protein-protein interactions involved in Alzheimer’s disease and design potential therapeutics against them. She has developed several series of different compounds against a key drug target in Alzheimer’s disease, as well as leading a large HTS European grant collaboration; yielding two distinct analogue series of molecules which will shortly be entering in vivo pre-clinical trials.

 Prof. Albert Sickmann Sickmann is the chairman of the Leibniz - Institut für Analytische Wissenschaften - ISAS - e.V. in Dortmund and Berlin. His research interest is focused on platelet activation and inhibition, which is tightly regulated by the integration of fast and highly complex signaling pathways. He develops OMICS technologies to dissect individual signaling hubs to provide an insight in underlying molecular mechanisms and facilitate future options for better diagnostics and individual treatment.

 

Prof. Ian Young is Professor of Medicine at Queen’s University Belfast, and Deputy Medical Director and Consultant Chemical Pathologist at Belfast Health and Social Care Trust.  In addition, he is Chief Scientific Advisor to the Department of Health, Northern Ireland, and Director of Research for Health and Social Care. His main clinical and research interests are in nutrition and lipid metabolism, particularly in relation to cardiovascular disease prevention and management of patients with complex lipid disorders.   He is currently President of the Association for Clinical Biochemistry and Laboratory Medicine, UK, and Chair of the Joint Committee for Traceability in Laboratory Medicine (JCTLM). He is a member of the UK Government’s Scientific Advisory Committee on Nutrition, and the Scientific Advisory Board of the UK National Institute of Biological Standards and Controls.  He is Associate Editor for Clinical Chemistry.